Icatibant Glenmark (Icatibant)

Icatibant works as a selective antagonist of the bradykinin B2 receptor. By preventing bradykinin from binding, it stops the cascade that leads to vasodilation and increased vascular permeability, thereby reducing the swelling that characterises hereditary angioedema attacks.

The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. The medication is administered subcutaneously, and the exact regimen should be followed as directed by the prescriber.

Safety of icatibant in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other therapies such as C1‑inhibitor concentrates replace the deficient protein. Icatibant provides rapid symptom relief through receptor blockade, while C1‑inhibitor products work by restoring the missing inhibitor. Choice depends on clinical response, route preference and patient-specific factors.

Icatibant should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period, and return the product to refrigeration promptly.

Icatibant is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver. The site should be rotated for repeated doses to minimize local irritation.

The most serious risks include anaphylaxis, severe angioedema that may worsen despite treatment, and hypotension. Patients should be monitored closely after injection, and any signs of severe allergic reaction or worsening swelling require immediate medical attention.

Icatibant is contraindicated in patients with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for individuals taking ACE inhibitors or neprilysin inhibitors, as the combined effect on bradykinin may increase the risk of angioedema.